Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Liabilities and Shareholders Equity (2017 - 2025)

Historic Liabilities and Shareholders Equity for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $175.5 million.

  • Aclaris Therapeutics' Liabilities and Shareholders Equity fell 376.11% to $175.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $783.1 million, marking a year-over-year increase of 953.47%. This contributed to the annual value of $220.3 million for FY2024, which is 1161.17% up from last year.
  • Latest data reveals that Aclaris Therapeutics reported Liabilities and Shareholders Equity of $175.5 million as of Q3 2025, which was down 376.11% from $189.1 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Liabilities and Shareholders Equity registered a high of $288.0 million during Q2 2021, and its lowest value of $161.1 million during Q2 2024.
  • Its 5-year average for Liabilities and Shareholders Equity is $219.6 million, with a median of $220.3 million in 2024.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 26646.27% in 2021, then crashed by 3164.79% in 2024.
  • Over the past 5 years, Aclaris Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $251.2 million in 2021, then increased by 1.35% to $254.6 million in 2022, then decreased by 22.46% to $197.4 million in 2023, then grew by 11.61% to $220.3 million in 2024, then decreased by 20.33% to $175.5 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $175.5 million for Q3 2025, versus $189.1 million for Q2 2025 and $198.1 million for Q1 2025.